This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate (REPLACE-CV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05605964
Recruitment Status : Recruiting
First Posted : November 4, 2022
Last Update Posted : November 21, 2023
Information provided by (Responsible Party):
Myovant Sciences GmbH

Brief Summary:
This is a randomized study to evaluate the risk of major adverse cardiovascular events (MACE) for relugolix compared with leuprolide acetate. This study will collect clinical and cardiovascular risk factor data on patients ages 18 and older who are receiving relugolix or leuprolide acetate for their prostate cancer or as adjunct to radiation therapy with a treatment plan to be on androgen deprivation therapy (ADT) for at least one year.

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: Relugolix Drug: Leuprolide Acetate Phase 3

Detailed Description:

Eligible patients will be randomized (1:1) to receive either relugolix or leuprolide acetate for prostate cancer or as an adjunct to primary or salvage radiation therapy. Patients who experience major adverse cardiovascular events (MACE) during the trial will be encouraged to stay on the study and continue to fill out questionnaires every 3 months. Each patient will also be asked to provide information regarding alternative contacts (eg, close relatives or friends, or primary care physician or cardiologist). In addition, patients will provide consent to obtain medical records (eg, hospitalizations, emergency room visits and clinic notes) for additional information, when appropriate.

The primary endpoint in this study will be the time to first adjudicated MACE (nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death). A surveillance approach will be used to collect clinical and cardiovascular risk data on patients receiving relugolix or leuprolide acetate for their prostate cancer. A rigorous, blinded adjudication of MACE by an independent clinical event adjudication committee (CEC) is included.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 2250 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Relugolix Versus Leuprolide in Patients With Prostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (REPLACE-CV)
Actual Study Start Date : January 25, 2023
Estimated Primary Completion Date : February 28, 2027
Estimated Study Completion Date : February 28, 2027

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Prostate Cancer

Arm Intervention/treatment
Experimental: Relugolix
Oral relugolix 120 mg once daily with a loading dose of 360 mg on Day 1
Drug: Relugolix
Relugolix tablet
Other Names:
  • TAK-385
  • MVT-601
  • RVT-601
  • T-1331285

Active Comparator: Leuprolide Acetate
Subcutaneous or intramuscular leuprolide acetate 22.5 mg 3-M depot or 45 mg 6-M injection
Drug: Leuprolide Acetate
Leuprolide acetate injection
Other Name: Leuprolide

Primary Outcome Measures :
  1. Time to Major Adverse Cardiovascular Event (MACE) [ Time Frame: From date of enrollment until date of first confirmed MACE, assessed up to 5 years ]
    Time to first adjudicated MACE defined as non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death

Secondary Outcome Measures :
  1. Time Course of Events Related to MACE [ Time Frame: From date of enrollment until date of first confirmed MACE, assessed up to 5 years ]
    Time to first adjudicated MACE or death due to all cause, time to first adjudicated nonfatal or fatal myocardial infarction, time to first adjudicated nonfatal or fatal stroke, time to adjudicated cardiovascular death, time to recurrent adjudicated MACE, and time to start of ADT in combination with enzalutamide/abiraterone/apalutamide/darolutamide for disease progression

  2. Incidence of Safety Outcomes [ Time Frame: Screening; Day 1; 3, 6, 9, and 12 months; and every 3 months thereafter ]
    Incidence of selective safety data including all treatment-emergent serious adverse events, nonserious adverse events leading to discontinuation of relugolix or leuprolide acetate, and clinical laboratory tests as obtained per standard of care

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Has voluntarily signed and dated the informed consent form prior to baseline visit;
  • Is a male and 18 years of age or older on the day of signing and dating the informed consent form;
  • Patient has sufficient cognitive function in the investigator's opinion to complete the questionnaires and other activities related to the study;
  • Has a histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate;
  • Is, in the opinion of the investigator, a candidate for at least 1 year of continuous ADT for the management of prostate cancer with one of the following clinical disease state presentations:

    • Evidence of biochemical (prostate-specific antigen [PSA], confirmed with two measurements at least one week apart) or clinical relapse following local primary intervention with curative intent (such as surgery, radiation therapy, cryotherapy, or high-frequency ultrasound and not a candidate for salvage treatment by surgery);
    • Newly diagnosed hormone-sensitive metastatic disease (metastases in regional lymph node[s] are considered N1 and will, therefore, be stratified as non-metastatic);
    • Advanced localized disease unlikely to be cured by local primary intervention with curative intent;
    • Patients receiving primary or salvage radiation therapy with adjuvant ADT;
  • Patients with high-risk cardiovascular disease defined as prior history of MACE (myocardial infarction, stroke, coronary revascularization [including percutaneous procedures] or revascularization affecting cerebral blood flow [including carotid procedures]) > 1 month before enrollment in the study; OR
  • Patients with ≥ 3 of the following cardiovascular risk factors:

    • Age (≥ 55 years of age);
    • Hypertension defined as self-reported high blood pressure, or use of a blood pressure-lowering medication;
    • Diabetes defined as self-reported diabetes or use of hypoglycemic medication;
    • Dyslipidemia defined as self-reported high cholesterol or use of a lipid-lowering medication;
    • Current cigarette use, defined as smoking within the year prior to the screening visit;
    • Family history of cardiovascular disease, defined as a myocardial infarction or stroke or coronary revascularization or revascularization affecting cerebral blood flow (ie, carotid procedures) or sudden death in a first-degree relative < 60 years old;
  • Serum testosterone before starting relugolix or leuprolide acetate of ≥ 150 ng/dL (1.50 ng/mL or 5.2 nmol/L) within 6 months prior to screening;
  • Serum PSA concentration of > 2.0 ng/mL (2.0 μg/L) or, when applicable, post radical prostatectomy of > 0.2 ng/mL (0.2 μg/L) within 6 months prior to screening (by medical history);
  • Patients, in the opinion of the investigator, must be equally eligible for either treatment in the study. If either the patient or the physician has a strong preference that one of the treatments be prescribed over the other, the patient must not be enrolled;
  • Patients must not be participating or intending to participate in an interventional therapeutic study.

Exclusion Criteria:

  • Any significant cardiovascular conditions per the investigator within 1 month before study entry including but not limited to: myocardial infarction, stroke, New York Heart Association class III or IV heart failure, thromboembolic events, major cardiovascular or cerebrovascular procedures or any other condition that in the investigator's opinion puts the patient at unacceptable risk to enter the study;
  • Any major cardiovascular or cerebrovascular procedures planned within the 1 month after enrollment;
  • Patients with QT interval corrected for heart rate (QTc) determined using Fridericia's formula (QTcF; QTcF = QT/[R-R interval {RR}^0.33]) > 470 msec within 6 months of screening;
  • Uncontrolled hypertension (systolic blood pressure > 180 mm Hg or diastolic blood pressure > 110 mm Hg) at the time of screening;
  • Previously received gonadotropin-releasing hormone (GnRH) receptor agonist (eg, leuprolide, goserelin, histrelin, triptorelin), GnRH receptor antagonist, or other forms of ADT (estrogen or antiandrogen) for > 18 months total duration. If ADT was received for ≤ 18 months total duration, then that therapy must have been completed at least 12 months prior to baseline. Once enrolled in the study, patients may be treated with ADT and anti-androgen (abiraterone, enzalutamide, apalutamide, darolutamide);
  • Metastases to brain per prior clinical evaluation;
  • Prescriber plans to switch from relugolix to leuprolide acetate or another GnRH agonist or antagonist or from leuprolide acetate to relugolix or another GnRH agonist or antagonist during the study;
  • Treatment with any investigational product within 28 days or 5 half-lives (whichever is longer). Exception: treatment for prostate cancer with any investigational products where the mechanism of action is testosterone lowering. In this circumstance, there must be a minimum 12-month treatment free interval;
  • Active malignancy beyond prostate cancer with the exception of the following:

    • Adequately treated basal cell carcinoma or squamous cell carcinoma of the skin;
    • Adequately treated Stage I cancer from which the patient is currently disease-free for ≥ 2 years;
    • Any other cancer from which the patient has been disease-free for ≥ 5 years;
    • Other malignancy upon agreement with the medical monitor.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT05605964

Layout table for location contacts
Contact: Clinical Trials at Myovant 650-278-8743

Show Show 108 study locations
Sponsors and Collaborators
Myovant Sciences GmbH
Layout table for additonal information
Responsible Party: Myovant Sciences GmbH Identifier: NCT05605964    
Other Study ID Numbers: MVT-601-056
First Posted: November 4, 2022    Key Record Dates
Last Update Posted: November 21, 2023
Last Verified: November 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Myovant Sciences GmbH:
prostate cancer
leuprolide acetate
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Genital Diseases
Urogenital Diseases
Prostatic Diseases
Male Urogenital Diseases
Fertility Agents, Female
Fertility Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Androgen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists